Introduction & Agenda

  1. Letter to Participants from the Chairs
  2. Meeting Agenda
  3. Discussion Questions Preview

Guidelines & Background

  1. January CT, Wann LS, Alpert JS, et. al. 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;64(21):1-76, (Section 4: Prevention of Thromboembolism).
  2. Heidbuchel H, Verhamme P, Alings M, et al. Updated European Heart Rhythm Association practical guide on the use of non-vitamin-K antagonist anticoagulants in patients with non-valvular atrial fibrillation: Executive Summary June 2016. Accessed July 5, 2016. This is an abridged version of an article published in Europace: Heidbuchel  H, Verhamme P, Alings M, et al. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace. 2015;17:1467–1507.
  3. Ruff C, Ansell J. North American Thrombosis Forum, AF Action Initiative Consensus Document The American Journal of Medicine. 2016;129:S1-S29.
  4. Culebras, A, Messé, S R, Chaturvedi, S, et al. Summary of Evidence-Based Guideline Update: Prevention of Stroke in Nonvalvular Atrial Fibrillation: Report to the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2014; 83(13):1220-1.        

Reversal Strategies

  1. Siegal DM, Curnutte JT, Connolly SJ, et al. Andexanet alfa for the reversal of Factor Xa inhibitor activity. N Engl J Med.2015;373(25):2413–2424.
  2. Pollack CV, Reilly PA, Eikelboom J, et al. Idarucizumab for Dabigatran reversal. N Engl J Med. 2015;373(6):511-20.
  3. Ruff C, Giugliano R, Antman EM. Management of Bleeding With Non–Vitamin K Antagonist Oral Anticoagulants in the Era of Specific Reversal Agents. Circulation 2016;134(3):248-61.


DAPT Guidelines & Trials

  1. Levine GN, Bates ER, Bittl JA, et al. 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2016;68(10):1082-1115.
  2. Gibson M, Mehran R, Bode C, et al. An open-label, randomized, controlled, multicenter study exploring two treatment strategies of rivaroxaban and a dose-adjusted oral vitamin k antagonist treatment strategy in subjects with atrial fibrillation who undergo percutaneous coronary intervention (PIONEER AF-PCI). Am Heart J. 2015;169:472-478.
  3. Cannon CP, Gropper S, Bhatt DL, et al. Design and Rationale of the RE-DUAL PCI Trial: A Prospective, Randomized, Phase 3b Study Comparing the Safety and Efficacy of Dual Antithrombotic Therapy With Dabigatran Etexilate Versus Warfarin Triple Therapy in Patients With Nonvalvular Atrial Fibrillation Who Have Undergone Percutaneous Coronary Intervention With Stenting. Clinical Cardiology. 2016. DOI:10.1002/clc.22572.

Complex Patients

  1. Kovacs RJ, Flaker GC, Saxonhouse SJ, Doherty JU, Birtcher KK, et al. Practical Management of Anticoagulation in Patients With Atrial Fibrillation. J Am Coll Cardiol. 2015;65(13):1340-60.
  2. Valgimigli M, Patrono C. Questions and answers on coronary revascularization: a companion document of the 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation European Heart Journal. 2015. DOI: 10.1093/eurheartj/ehv408.
  3. Raccah B, Perlman A, Danenberg HD, et al. Major Bleeding And Hemorrhagic Stroke With Direct Oral Anticoagulants In Patients With Renal Failure: Systematic Review And Meta-Analysis Of Randomized Trials. Chest. 2016;149(6):1516-1524.
  4. Frontera, JA, Lewin III, JJ, Rabinstein, AA et al. Guideline for Reversal of Antithrombotics in Intracranial Hemorrhage: A Statement for Healthcare Professionals from the Neurocritical Care Society and Society of Critical Care Medicine. Neurocrit Care. 2016;24:6-46.

Presentations

  1. Keynote_Crowther_Clinical Deep Dive Into Reversals
  2. Session 1_Merli_Reversal of DOACs
  3. Session 2_Dobesh and Cuker_Expert Consensus Decision Pathway on Management of Bleeding in Anticoagulation
  4. Session 3_Levine_DAPT Guidelines
  5. Session 4_Hucker_Clinical Case Challenges Presenter 1
  6. Session 4_Kanzaria_Clinical Case Challenges Presenter 2
  7. Session 4_Khorana_Cancer Associated Thrombosis
  8. Session 4_Kline_ED Care in Era of NOACs
  9. Session 4_Messe_Stroke AF and Anticoagulation
  10. Session 4_Russo_Role of LAAO devices